Study #2023-0582
IDE196 (Darovasertib) in combination with Crizotinib versus investigator's choice of treatment as first-line therapy in hla-a2 negative metastatic uveal melanoma (dar-um-2)
MD Anderson Study Status
Enrolling
Treatment Agent
IDE196, Crizotinib, Pembrolizumab, Ipilimumab, Nivolumab, Dacarbazine
Description
This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Metastatic Uveal Melanoma
Study phase:
Phase II/III
Physician name:
Alexandra Ikeguchi
Department:
Melanoma Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.